Radioimmunoscintigraphy of pancreatic cancer in tumor-bearing athymic nude mice using 99mtechnetium-labeled anti-KL-6/MUC1 antibody

Abstract

99mTc-labeled anti-KL-6/MUC1 antibody appears to be a promising agent as a tumor-specific radiotracer for pancreatic cancer.

MUC1-Targeted Radiopharmaceuticals in Cancer Imaging and Therapy

“…Preclinical studies were investigated in BALB/ c mice bearing breast tumors indicating the accumulation of the radiocomplex at the tumor site with a high sensitivity and specificity. The results demonstrated that 111 In-DOTA-PR81 could be contemplated as a suitable probe for a prognostic imaging of antigens in oncology. 75 The results of radiolabeled anti-MUC1 PR81 mAb analogues are summarized in Table 1.…”

“…54 For a radioisotope that is to be used for diagnosis, it must emit γ-rays with enough energy so that it can escape the body, and it should have a short enough half-life to be decayed away soon after the imaging is completed. For single photon-emission tomography (SPECT), γ-emitters with energies in the range from 100 to 250 keV are optimal and are mainly represented by 99m Tc, 123 I, and 111 In. High-energy positron-emitters such as 18 F, 68 Ga, 64 Cu, and 11 C can be used for positron-emission tomography (PET) by emitting 511 keV photons.…”

“…These results indicated the potential of this radioimmunoconjugate for PET imaging of MUC1 expression tumors. 64,74 In 2020, PR81 radiolabeled with 111 In was developed for the detection of MUC1 expressing breast cancers. 111 In-DOTA-PR81 was produced in a high radiochemical yield and a high in vitro and in vivo stability.…”

“…64,74 In 2020, PR81 radiolabeled with 111 In was developed for the detection of MUC1 expressing breast cancers. 111 In-DOTA-PR81 was produced in a high radiochemical yield and a high in vitro and in vivo stability. The radioimmunoconjugate represented immunoreactivity toward MCF7 cell line and MUC1 antigen.…”

“…Following intravesical administration of the radioimmunoconjugate, it was preferentially localized at a tumor relative to normal tissue (urothelium) with an uptake ratio of 8.3:1. 77 In another study Hughes et al investigated the C595 antibody coupled to 111 In for the staging of invasive bladder cancer. 111 In-labeled C595 was administrated intravesically to 12 patients with superficial and invasive bladder cancers and underwent planar γ-scintigraphy.…”